These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 4714712)

  • 1. Pills, potions and persuasion, or the 'medicine explosion'.
    Kane GJ
    S Afr Med J; 1973 Jun; 47(25):1127-8. PubMed ID: 4714712
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of generic or patent medicines in the Netherlands.
    Gebhardt DO
    J Med Ethics; 2005 Jul; 31(7):409. PubMed ID: 15994361
    [No Abstract]   [Full Text] [Related]  

  • 3. To inform or persuade? Direct-to-consumer advertising of prescription drugs.
    Berndt ER
    N Engl J Med; 2005 Jan; 352(4):325-8. PubMed ID: 15673797
    [No Abstract]   [Full Text] [Related]  

  • 4. Prescription drug pushers. Patents and ads are the big reasons pills are priced like perfume and caviar.
    Sherrid P
    US News World Rep; 2000 Oct; 129(17):40-2. PubMed ID: 11184929
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial: Standardization of drug names--a commentary.
    Lee A
    JAMA; 1974 Jul; 229(5):560-2. PubMed ID: 4406903
    [No Abstract]   [Full Text] [Related]  

  • 6. Direct-to-consumer advertising--where does the public interest lie?
    Saunders B
    N Z Med J; 2003 Aug; 116(1180):U557; discussion U557. PubMed ID: 14581978
    [No Abstract]   [Full Text] [Related]  

  • 7. [Brand names in the pharmacopeia].
    Offerhaus L; Zwieten PA
    Ned Tijdschr Geneeskd; 1977 Aug; 121(35):1366-9. PubMed ID: 895924
    [No Abstract]   [Full Text] [Related]  

  • 8. The Industries Assistance Commission draft report on pharmaceutical products.
    Med J Aust; 1986 Mar; 144(5):253-63. PubMed ID: 3587097
    [No Abstract]   [Full Text] [Related]  

  • 9. New Zealand deserves better. Direct-to-consumer advertising (DTCA) of prescription medicines in New Zealand: for health or for profit?
    Toop L; Richards D; Saunders B
    N Z Med J; 2003 Aug; 116(1180):U556; discussion U556. PubMed ID: 14581976
    [No Abstract]   [Full Text] [Related]  

  • 10. Why use generic names?
    Palmer DD
    Hawaii Med J; 1968; 27(4):321-4. PubMed ID: 5644836
    [No Abstract]   [Full Text] [Related]  

  • 11. Are drug proprietary names necessary?
    D'Arcy PF; Hadden DR
    Adverse Drug React Toxicol Rev; 2000 Jun; 19(2):117-21. PubMed ID: 10967746
    [No Abstract]   [Full Text] [Related]  

  • 12. The Canadian Medical Association brief to the Parliamentary Committee on Food and Drugs.
    Can Med Assoc J; 1966 Aug; 95(7):324-30. PubMed ID: 5969351
    [No Abstract]   [Full Text] [Related]  

  • 13. Direct-to-consumer advertising--education or emotion promotion?
    Wolfe SM
    N Engl J Med; 2002 Feb; 346(7):524-6. PubMed ID: 11844857
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

  • 15. Trade names or approved names. Part II. Points of view. The pharmaceutical company.
    Hoare RG
    Postgrad Med J; 1974 Feb; 50(580):85-7. PubMed ID: 4465781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Disclosure of retail prices for prescription drugs". Response of the American Pharmaceutical Association to the June 14, 1974, inquiry of the Federal Trade Commission.
    J Am Pharm Assoc; 1974 Oct; 14(10):538-42, 577-8. PubMed ID: 4418393
    [No Abstract]   [Full Text] [Related]  

  • 17. Patent nonsense: evidence tells of an industry out of social control.
    Mintzberg H
    CMAJ; 2006 Aug; 175(4):374. PubMed ID: 16908900
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicines pricing singled out.
    Buchanan E
    S Afr Med J; 2004 May; 94(5):334. PubMed ID: 15211941
    [No Abstract]   [Full Text] [Related]  

  • 19. [Proposals for the legal control of the testing and introduction of drugs based on a comparison of drug laws in other countries].
    Burow W; Lüllmann H
    Schriftenr Geb Off Gesundheitswes; 1971; 31():1-64. PubMed ID: 5153578
    [No Abstract]   [Full Text] [Related]  

  • 20. Free rein for drug ads? A slowdown in FDA review has left consumers more vulnerable to misleading messages.
    Consum Rep; 2003 Feb; 68(2):33-7. PubMed ID: 12516586
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.